Identity and synonyms
Identity follows the supplied name and synonyms; no additional identity description is supplied.
Synonyms: MK-677 · MK-0677
Nonpeptide agent · Nonpeptide small molecule
Detailed molecular class: Non-peptide ghrelin mimetic
Supplied sequence or chemical reference
PubChem CID: 178024
Molecular formula: C27H36N4O5S
IUPAC: 2-amino-2-methyl-N-[(2R)-1-(1-methylsulfonylspiro[2H-indole-3,4'-piperidine]-1'-yl)-1-oxo-3-phenylmethoxypropan-2-yl]propanamide
Source: PC-IBUTAMOREN
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Stimulates GH/IGF-1 through ghrelin-receptor pathways.
Evidence and critical reading
Reported scientific and empirical uses
GH/IGF hormonal axis
MK-677 is an oral ghrelin mimetic; a shared GH target does not make it a peptide.
Human evidence
Older-adult trial measured body composition; increased lean mass did not establish improved strength/function.
Preclinical evidence
Endocrine effects do not establish healthy longevity.
Critical reading and limitations
In older adults it increased fat-free mass without equivalent strength/function improvement; composition is not performance.
Evidence applies to the exact molecule, formulation, route, population and endpoint studied. Supplier identity, purity and clinical equivalence are unverified.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.
25 mg · Amount per administration
- Frequency
- Daily
- Duration
- One year, selected analysis
- Route
- Oral
- Context
- 65 adults aged 60–81; body composition/function and metabolic safety.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID18981485 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
Jurisdiction-specific approval not verified in this card; do not infer global nonapproval.
Adverse effects and unknowns
FDA cites a heart-failure safety signal in a hip-fracture trial; glucose regulation and edema are relevant.
Glucose, edema and a heart-failure signal in another trial are material limits.
Contraindications
See supported safety statements and exact product label; a complete contraindication set has not been established for this catalog material.
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Only explicitly cited interactions may be asserted; unstudied combinations remain unknown, not interaction-free.
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID18981485 · Randomized controlled trial
Adults aged 60–81.
Daily oral, one-year analysis.
Fat-free mass increased without equivalent strength/function benefit; glucose changes/edema.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 65
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
ibutamoren · 8 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT06948214 · Phase 3 Study of LUM-201 in Children With Growth Hormone DeficiencyRegistry status: RecruitingLast update posted: October 9, 2026Query verification: October 16, 2026
NCT05364684 · The Impact of Ibutamoren on Nonalcoholic Fatty Liver DiseaseRegistry status: CompletedLast update posted: January 6, 2026Query verification: October 16, 2026
NCT01343641 · Growth Hormone Secretagogue MK-0677's Effect on Lean Body Mass in Chronic Kidney Disease Stage 4/5 SubjectsRegistry status: WithdrawnLast update posted: May 14, 2018Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-IBUTAMOREN
PubChem ibutamoren (CID 178024)
October 16, 2026
- PMID18981485
Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO.
October 16, 2026
- R06